AbCellera Biologics NASDAQ: ABCL is preparing to advance its experimental hot flash treatment ABCL635 into late-stage studies, with a registrational trial potentially starting around the middle of 2027, Chief Executive Carl Hansen said at the Jefferies 2026 Global Healthcare Conference in London.
The company expects to release additional Phase 2 data early next year and is working toward regulatory alignment and preparing manufacturing and delivery devices for the trial, Hansen said. AbCellera is developing the antibody as a non-hormonal treatment for vasomotor symptoms associated with menopause and hormone deprivation in cancer therapy.
More Phase 2 data ahead
AbCellera reported four-week Phase 2 results in August after patients received a single 600-milligram dose. Hansen said the dose was intended to mimic the steady-state exposure of a 300-milligram monthly injection.
Hansen said the treatment showed stronger efficacy than approved small-molecule medicines, including a greater reduction in the frequency and severity of hot flashes. He said 37% of women who started with an average of 10 moderate-to-severe episodes a day reported no episodes at four weeks, while about 60% had a reduction of at least 90%.
The next data release will cover a 12-week period following the initial dose, as well as four-week results after another dose in an open-label extension. Both the original treatment and placebo groups receive the drug in the extension.
Hansen cautioned that efficacy is expected to decline during the eight-week washout period after the initial four-week assessment. Even a return to zero efficacy by 12 weeks would be acceptable, he said, because a single dose followed by that interval is not the intended treatment schedule.
The additional data will help inform dosing and provide an early look at response after two doses. Hansen said the company wants to see efficacy comparable to the initial four-week result and maintain a clean safety profile.
Safety and trial planning
Hansen said AbCellera had seen no evidence of liver toxicity or a gastrointestinal safety signal in the study so far. Headaches occurred roughly twice as often in the treatment group as in the control group across the Phase 1 and Phase 2 studies, he said, but were generally mild and resolved on their own in a median of about one day.
The company has started engaging with regulators and plans meetings with the U.S. Food and Drug Administration, the European Medicines Agency and other authorities after the trial is complete, Hansen said. AbCellera expects to disclose its development plan once it has regulatory alignment.
For menopause-related symptoms, Hansen said the company currently expects two placebo-controlled registrational trials involving around 1,500 patients, with frequency and severity endpoints at four and 12 weeks and a safety extension. The company is also considering separate head-to-head studies, though he said those would not be necessary or appropriate for the registrational program.
The key steps before starting the registrational study are regulatory alignment and preparing manufacturing and delivery devices, Hansen said. AbCellera is considering a prefilled syringe or an autoinjector for a single 300-milligram shot.
Other programs and strategy
AbCellera also plans studies for hot flashes associated with hormone deprivation in breast and prostate cancer. Hansen said the breast cancer program could potentially move into late-stage studies more quickly, while the prostate cancer indication may require a Phase 2 study first.
The company is developing ABCL992, a longer-acting analog of ABCL635 that Hansen said could potentially support at least quarterly dosing. He emphasized that the work does not signal a retreat from ABCL635 and said the two products could coexist, though their eventual positioning has not been determined.
AbCellera is not seeking a partner for late-stage development, Hansen said. For commercialization, it is considering a direct-to-consumer or telehealth model that could be pursued independently or with a partner.
Hansen said two other programs, ABCL688 and ABCL386, are in activities intended to support applications to begin human trials and could enter the clinic next year. He said AbCellera has about $900 million in liquidity to support its lead programs and broader pipeline.
About AbCellera Biologics (NASDAQ:ABCL)
AbCellera Biologics Inc. is a biotechnology company headquartered in Vancouver, Canada. It discovers and develops antibody-based medicines, using laboratory and computational tools to identify and optimize antibodies that may be developed into treatments for disease. The company works with pharmaceutical and biotechnology partners on antibody discovery and drug development, while also advancing a portfolio of its own therapeutic candidates. Its work spans early-stage research through preclinical and clinical development, with programs focused on areas including cancer and immune-related diseases.
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider AbCellera Biologics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and AbCellera Biologics wasn't on the list.
While AbCellera Biologics currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Robotics and automation are rapidly becoming essential infrastructure across healthcare, manufacturing, logistics, and many other industries. "Physical AI" is coming. Learn which seven companies are most positioned to benefit as intelligent robots enter the workforce.
Get This Free Report
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Like this article? Share it with a colleague.
Link copied to clipboard.